Survey says people want neurological diagnosis, regardless of cure

GE's Vizamyl, a radioactive diagnostic agent, was approved by the FDA for use in Positron Emission Tomography (PET) imaging to measure levels of beta amyloid in patients being evaluated for Alzheimer's disease.--Courtesy of GE

The argument for the importance of patient diagnosis often relies upon the efficacy of subsequent treatment. But according to a recent study, three-quarters of people would want to know if they have a particular neurological disorder even if it had no cure.

The 10,000-adult, 10-country survey was sponsored by GE Healthcare ($GE), which obviously has a huge financial stake in the sale of diagnostic and imaging products. Its Alzheimer's imaging agent, Vizamyl, recently got a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use; that follows a nod from the FDA last year. The study basically makes an argument for why insurers should cover it.

Vizamyl is the second imaging agent to be approved by the FDA to identify amyloid β in the brain; Amyvid from Eli Lilly ($LLY) was the first. GE Healthcare has committed to investing more than $500 million into neurological disorder research between 2010 and 2020.

According to the survey, although most people think diagnosis should be funded by either government or private health insurance, more than half said they would be willing to pay for it themselves. But in India and China--where the burden of healthcare expenses often falls to the patient--71% and 83% of responders, respectively, said they would be willing to pay for diagnostics themselves.

Diagnostic tools are available to identify neurological diseases such as Alzheimer's and Parkinson's. There is also no cure for dementia, of which Alzheimer's disease is a common form.

"What these statistics tell us is just how strongly people feel about tackling neurological disorders like dementia," Executive Director of Alzheimer's Disease International Marc Wortmann said in a statement. Almost 44 million people have dementia worldwide, a figure that's expected to double in the next 20 years.

Wortmann added, "Although there is no cure yet, a timely diagnosis is useful for people with dementia to get access to current treatment, services and support, both medical and nonmedical."

Symptom management is one option with early diagnosis, even if no cure is available. Interestingly, even more respondents, 81%, would want to know a neurological diagnosis for a loved one than for themselves. While most of them recognized memory loss and disorientation as signs of dementia, less than half of respondents were able to identify other common symptoms such as language problems, personality, mood and behavior changes, and loss of initiative.

"Although there are currently no cures for many neurological disorders, there are symptom-modifying therapies and approaches available if detected early enough," summed up GE Healthcare Director of PET Neurology for GE Healthcare Dr. Ben Newton.

- here is the release about the study